Secondary hemorrhage after bipolar transurethral resection and vaporization of prostate

Chi-Hang Yee, Joseph Hon-Ming Wong, Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Chi-Kwok Chan, Eddie Shu-Yin Chan, See-Ming Hou, Chi-Fai Ng, Chi-Hang Yee, Joseph Hon-Ming Wong, Peter Ka-Fung Chiu, Jeremy Yuen-Chun Teoh, Chi-Kwok Chan, Eddie Shu-Yin Chan, See-Ming Hou, Chi-Fai Ng

Abstract

Introduction: We evaluated the factors associated with secondary hemorrhage after bipolar transurethral resection of prostate (TURP) and vaporization of prostate.

Materials and methods: The perioperative data of patients undergoing endoscopic surgery for benign prostatic hyperplasia (BPH) were prospectively collected. Procedures involved included bipolar TURP, bipolar vaporization of prostate, and hybrid bipolar TURP/vaporization of prostate. Secondary hemorrhage was defined as bleeding between 48 h and 30 days postsurgery requiring hospital attendance with or without admission. Risk factors for secondary hemorrhage were analyzed.

Results: From 2010 to 2013, 316 patients underwent bipolar surgery for BPH. Bipolar TURP accounted for 48.1% of the procedures, bipolar vaporization accounted for 20.3% of the procedures, and the rest were hybrid TURP/vaporization of prostate. Among this cohort of patients, fifty patients had secondary hemorrhage with hospital attendance. Consumption of platelet aggregation inhibitors (PAIs) was found to be associated with secondary hemorrhage (P < 0.0005). Age, prostate volume, operation type, the use of 5-alpha reductase inhibitors, and being with a urethral catheter before operation were not found to be statistically significant risk factors for secondary hemorrhage.

Conclusions: Secondary hemorrhage after bipolar surgery for BPH is a common event. Consumption of PAI is a risk factor for such complication.

Keywords: Benign prostatic hyperplasia; hemorrhage; transurethral resection of prostate.

References

    1. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The burden of lower urinary tract symptoms: Evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(Suppl 3):4–11.
    1. Yee CH, Li JK, Lam HC, Chan ES, Hou SS, Ng CF. The prevalence of lower urinary tract symptoms in a Chinese population, and the correlation with uroflowmetry and disease perception. Int Urol Nephrol. 2014;46:703–10.
    1. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099–109.
    1. Mamoulakis C, Ubbink DT, de la Rosette JJ. Bipolar versus monopolar transurethral resection of the prostate: A systematic review and meta-analysis of randomized controlled trials. Eur Urol. 2009;56:798–809.
    1. Reich O, Schlenker B, Gratzke C, Tilki D, Riecken M, Stief C, et al. Plasma vaporisation of the prostate: Initial clinical results. Eur Urol. 2010;57:693–7.
    1. Yip SK, Chan NH, Chiu P, Lee KW, Ng CF. A randomized controlled trial comparing the efficacy of hybrid bipolar transurethral vaporization and resection of the prostate with bipolar transurethral resection of the prostate. J Endourol. 2011;25:1889–94.
    1. Wasson JH, Reda DJ, Bruskewitz RC, Elinson J, Keller AM, Henderson WG. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. N Engl J Med. 1995;332:75–9.
    1. Fowler FJ, Jr, Wennberg JE, Timothy RP, Barry MJ, Mulley AG, Jr, Hanley D. Symptom status and quality of life following prostatectomy. JAMA. 1988;259:3018–22.
    1. Yang EJ, Li H, Sun XB, Huang L, Wang L, Gong XX, et al. Bipolar versus monopolar transurethral resection of the prostate for benign prostatic hyperplasia: Safe in patients with high surgical risk. Sci Rep. 2016;6:21494.
    1. da Silva RD, Bidikov L, Michaels W, Gustafson D, Molina WR, Kim FJ. Bipolar energy in the treatment of benign prostatic hyperplasia: A current systematic review of the literature. Can J Urol. 2015;22(Suppl 1):30–44.
    1. Harvey MH, Leese T, Lloyd D, Osborn DE. Antibiotic prophylaxis and secondary haemorrhage following transurethral resection of the prostate: A prospective trial. Br J Urol. 1986;58:450–2.
    1. Ehrlich Y, Yossepowitch O, Margel D, Lask D, Livne PM, Baniel J. Early initiation of aspirin after prostate and transurethral bladder surgeries is not associated with increased incidence of postoperative bleeding: A prospective, randomized trial. J Urol. 2007;178:524–8.
    1. Skolarikos A, Rassweiler J, de la Rosette JJ, Alivizatos G, Scoffone C, Scarpa RM, et al. Safety and efficacy of bipolar versus monopolar transurethral resection of the prostate in patients with large prostates or severe lower urinary tract symptoms: Post hoc analysis of a european multicenter randomized controlled trial. J Urol. 2016;195:677–84.
    1. Stucki P, Marini L, Mattei A, Xafis K, Boldini M, Danuser H. Bipolar versus monopolar transurethral resection of the prostate: A prospective randomized trial focusing on bleeding complications. J Urol. 2015;193:1371–5.
    1. Maddox M, Pareek G, Al Ekish S, Thavaseelan S, Mehta A, Mangray S, et al. Histopathologic changes after bipolar resection of the prostate: Depth of penetration of bipolar thermal injury. J Endourol. 2012;26:1367–71.
    1. Akgül T, Nuhoglu B, Polat O, Ayyildiz A, Astarci M, Germiyanoglu C, et al. An in vitro study comparing the coagulation and cautery effects of bipolar and unipolar cutting modalities on prostatic tissue. Urol Int. 2009;83:458–62.
    1. Ko R, Tan AH, Chew BH, Rowe PE, Razvi H. Comparison of the thermal and histopathological effects of bipolar and monopolar electrosurgical resection of the prostate in a canine model. BJU Int. 2010;105:1314–7.
    1. Heer R, Glendinning RJ, Nesbitt CN, Pal D, Rix D, Menezes P, et al. Secondary haemorrhage following transurethral resection of bladder tumour paIs it always related to infection? Br J Med Surg Urol. 2012;5:61–6.
    1. Watson CJ, Deane AM, Doyle PT, Bullock KN. Identifiable factors in post-prostatectomy haemorrhage: The role of aspirin. Br J Urol. 1990;66:85–7.
    1. Patel PA, Fleisher LA. Aspirin, clopidogrel, and the surgeon. Adv Surg. 2014;48:211–22.
    1. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology. 2000;55:684–9.
    1. Lund L, Møller Ernst-Jensen K, Tørring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: A prospective randomized study. Scand J Urol Nephrol. 2005;39:160–2.
    1. Hahn RG, Fagerström T, Tammela TL, Van Vierssen Trip O, Beisland HO, Duggan A, et al. Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99:587–94.
    1. Tuncel A, Ener K, Han O, Nalcacioglu V, Aydin O, Seckin S, et al. Effects of short-term dutasteride and Serenoa repens on perioperative bleeding and microvessel density in patients undergoing transurethral resection of the prostate. Scand J Urol Nephrol. 2009;43:377–82.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere